A man with end-stage renal disease is now healthy enough to be discharged from the hospital, after becoming the first in the world to receive a kidney transplant from a genetically engineered pig.

Ranked No. 1 in Biotech Category and No. 34 overall on World’s 50 Most Innovative Companies list The company was named No. 1 in the Biotech category and ranked No. 34 on Fast Company’s 2026 World’s 50 ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation ...

IND supports Phase 1/2/3 study that will evaluate safety and efficacy at 24 weeks The first patient in the ongoing Multi-Patient Expanded Access study has surpassed seven months kidney function; a ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The local biotech whose ...

Biotech company eGenesis recently announced its implanted a pig kidney into a second human patient. This animal-to-human organ transplant, or xenotransplant, was made possible through advancements in ...

CAMBRIDGE, Mass. and IRVINE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- eGenesis, Inc. (“eGenesis”) and Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN ...

For three days in December, an ICU room at the Hospital of the University of Pennsylvania bore witness to the first-ever merging of two powerful new technologies poised to change the future of ...

An international partnership between eGenesis in the United States and PorMedTec in Japan has led to the successful production of genetically engineered porcine donors for use in transplantation.

Biotech startup eGenesis developed a gene-edited kidney that was successfully transplanted into a living patient last week. Its CEO says the company is just getting started. Last Thursday, surgeons at ...

Please provide your email address to receive an email when new articles are posted on . A xenotransplantation program received $191 million in Series D financing to pursue a first-in-human kidney ...

Biotechnology company eGenesis has raised $191 million in new venture capital to advance toward its first clinical trials after its genetically modified pig kidney was transplanted into a patient in a ...